# Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

> **NCT03667690** · PHASE3 · COMPLETED · sponsor: **Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 199 (actual)

## Conditions studied

- Candidemia
- Mycoses
- Fungal Infection
- Invasive Candidiases

## Interventions

- **DRUG:** Rezafungin for Injection
- **DRUG:** Caspofungin
- **DRUG:** Fluconazole
- **DRUG:** intravenous placebo
- **DRUG:** oral placebo

## Key facts

- **NCT ID:** NCT03667690
- **Lead sponsor:** Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-07
- **Primary completion:** 2021-10-07
- **Final completion:** 2021-10-07
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03667690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03667690, "Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03667690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*